Topics:

Roche's sweet spot: The $6B-$7B acquisition deal

Tools
Roche CFO Alan Hippe

Roche ($RHHBY) isn't likely to imitate its Big Pharma rivals who have been buying back their own shares to keep restive investors happy. Rather, top execs are on the lookout for new technologies that will make the pharma giant an even better competitor. And its sweet spot is the $6 billion to $7 billion mark as Roche stays in the hunt for buyouts--with a particular interest in gene sequencing. That's the bottom line for Chief Financial Officer Alan Hippe, who sat down with Bloomberg Industries analysts recently to discuss its deal strategy. Story

Filed Under